Figure 6. Silencing PVT1 downregulates the MAPK/NF-κB signaling pathway in oxLDL-induced HA-VSMCs and AS mice. (A) mRNA expression of MAPK and NF-κB in AS mice detected by qRT-PCR; (B) Protein levels of MAPK and NF-κB in AS mice detected by Western blot; (C) mRNA expression of MAPK and NF-κB in oxLDL-treated HA-VSMCs detected by qRT-PCR; (D) Protein levels of MAPK and NF-κB in oxLDL treated HA-VSMCs detected by Western blot. Compared to the oe-NC group, * p < 0.05, ** p < 0.01; compared to the si-NC group, # p < 0.05, ## p < 0.01. PVT1, plasmacytoma variant translocation 1; MAPK, mitogen-activated protein kinase; NF-κB, Nuclear factor-kappa B; oxLDL, oxidative low density lipoprotein; AS, atherosclerosis; HA-VSMCs, Human arterial vascular smooth muscle cells; oe, overexpression; NC, negative control.